CN112996534B - 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物 - Google Patents

结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物

Info

Publication number
CN112996534B
CN112996534B CN201980062030.6A CN201980062030A CN112996534B CN 112996534 B CN112996534 B CN 112996534B CN 201980062030 A CN201980062030 A CN 201980062030A CN 112996534 B CN112996534 B CN 112996534B
Authority
CN
China
Prior art keywords
alk
egf
bvn22e
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980062030.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112996534A (zh
Inventor
埃里克·东特
米格尔·安格尔·莫利纳-维拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insrebaio Ltd
Original Assignee
Insrebaio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insrebaio Ltd filed Critical Insrebaio Ltd
Publication of CN112996534A publication Critical patent/CN112996534A/zh
Application granted granted Critical
Publication of CN112996534B publication Critical patent/CN112996534B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980062030.6A 2018-08-07 2019-08-07 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物 Active CN112996534B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862715351P 2018-08-07 2018-08-07
US62/715,351 2018-08-07
US201862727056P 2018-09-05 2018-09-05
US62/727,056 2018-09-05
US201862748772P 2018-10-22 2018-10-22
US62/748,772 2018-10-22
US201862760529P 2018-11-13 2018-11-13
US62/760,529 2018-11-13
US201962822290P 2019-03-22 2019-03-22
US62/822,290 2019-03-22
PCT/IB2019/000905 WO2020030977A2 (en) 2018-08-07 2019-08-07 Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors

Publications (2)

Publication Number Publication Date
CN112996534A CN112996534A (zh) 2021-06-18
CN112996534B true CN112996534B (zh) 2025-11-18

Family

ID=68425157

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980062030.6A Active CN112996534B (zh) 2018-08-07 2019-08-07 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物

Country Status (11)

Country Link
US (1) US12257245B2 (enExample)
EP (1) EP3833384A2 (enExample)
JP (1) JP2021534094A (enExample)
KR (1) KR20210041571A (enExample)
CN (1) CN112996534B (enExample)
AU (1) AU2019319109A1 (enExample)
BR (1) BR112021002145A2 (enExample)
CA (1) CA3108236A1 (enExample)
IL (1) IL280632A (enExample)
MX (1) MX2021001398A (enExample)
WO (1) WO2020030977A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
WO2022256360A1 (en) * 2021-06-02 2022-12-08 Neuvogen, Inc. Tumor cell vaccines
WO2023059801A1 (en) * 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
KR102685187B1 (ko) 2021-10-15 2024-07-16 제이투에이치바이오텍 (주) Alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도
CA3236522A1 (en) * 2021-10-28 2023-05-04 In3Bio Ltd. Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
TW202339767A (zh) * 2022-01-18 2023-10-16 大陸商齊魯製藥有限公司 螺環芳基磷氧化物與抗ｅｇｆｒ抗體的聯用藥物組合物及其用途
WO2024017352A1 (zh) * 2022-07-22 2024-01-25 四川大学 用于rdaa阳性疾病的诊断和治疗的方法和试剂盒
WO2024249331A1 (en) * 2023-05-26 2024-12-05 The Board Of Regents Of The University Of Texas System Combined rtk and alk inhibition in rtk driven cancers
KR20250120789A (ko) 2024-02-02 2025-08-11 제이투에이치바이오텍 (주) E3 리가제 리간드 화합물, alk 및/또는 egfr 돌연변이 키나제 억제 효과를 나타내는 화합물 및 이의 의약 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US8828391B2 (en) * 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR20140064971A (ko) * 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
MX347772B (es) 2012-03-06 2017-05-12 Cephalon Inc Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.
US20150218652A1 (en) * 2012-08-31 2015-08-06 The Regents Of The Unversity Of Colorado, A Body Corporate Methods for diagnosis and treatment of cancer
US20160017431A1 (en) * 2014-03-28 2016-01-21 Driver Group Methods for Predicting EGFR Tyrosine Kinase Inhibitor Efficacy
CA2946538A1 (en) * 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
EP3303399A1 (en) * 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies
KR20180025888A (ko) * 2015-06-08 2018-03-09 제넨테크, 인크. 항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
JP7751357B2 (ja) 2017-07-18 2025-10-08 イン３バイオ・リミテッド 合成タンパク質およびその治療学的用途
RU2654695C1 (ru) 2017-07-28 2018-05-22 Акционерное Общество "Р-Фарм" (Ао "Р-Фарм") 8-(1-{ 4-{ (5-Хлор-4-{ (2-(диметилфосфорил)фенил)амино} пиримидин-2-ил)амино)-3-метоксифенил} пиперидин-4-ил)-1-метил-1,8-диазаспиро(4.5)декан-2-он и его фармацевтически приемлемые соли в качестве модулятора ALK и EGER, предназначенные для лечения рака

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation;Akihiko Miyanaga et al.;《Cancer》;20130529;第13卷(第262期);1-5 *
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors;Hirokazu Taniguchi et al.;《cancer research》;第108卷(第1期);摘要，第57页左栏倒数第1段，右栏第1段 *
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors;Hirokazu Taniguchi et al.;《cancer science》;20170131;第108卷(第1期);53-60 *
antitumor effects of anti-EGF antibodies generated by vaccination in NSCLC tumor cells;silvia Garcia-roman et al.;《cancer research》;20180701;第78卷(第13期);1-2 *
Antitumor effects of anti-EGF antibodies generated by vaccination in NSCLCtumor cells;Silvia Garcia-Roman et al.;《POSTER PRESENTATIONS - PROFFERED ABSTRACTS》;第78卷(第13期);背景、方法和结果 *
Hirokazu Taniguchi et al..Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.《cancer research》.2017,第108卷(第1期),摘要，第57页左栏倒数第1段，右栏第1段. *
Silvia Garcia-Roman et al..Antitumor effects of anti-EGF antibodies generated by vaccination in NSCLCtumor cells.《POSTER PRESENTATIONS - PROFFERED ABSTRACTS》.2018,第78卷(第13期),背景、方法和结果. *

Also Published As

Publication number Publication date
KR20210041571A (ko) 2021-04-15
MX2021001398A (es) 2021-08-16
JP2021534094A (ja) 2021-12-09
AU2019319109A1 (en) 2021-02-25
IL280632A (en) 2021-03-25
US12257245B2 (en) 2025-03-25
CA3108236A1 (en) 2020-02-13
CN112996534A (zh) 2021-06-18
BR112021002145A2 (pt) 2021-12-14
US20200046690A1 (en) 2020-02-13
WO2020030977A2 (en) 2020-02-13
EP3833384A2 (en) 2021-06-16
WO2020030977A3 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
CN112996534B (zh) 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物
CN107405401B (zh) 用于治疗癌症的pd-1/pd-l1抑制剂
TWI885529B (zh) 抗體-藥物結合物之用途
CN112512576A (zh) PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症
HK1221408A1 (zh) 用於治疗成胶质细胞瘤的组合疗法
CN103025353A (zh) 治疗方法
US12258389B2 (en) Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
CA3078806A1 (en) Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW202015738A (zh) 藉由投與抗ｈｅｒ２抗體－藥物結合物之ｈｅｒ２突變型癌症之治療
CN111629729A (zh) 治疗癌症的方法及组合疗法
WO2020249018A1 (zh) 治疗驱动基因阳性肺癌的联用药物组合物
US20220378891A1 (en) Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
CN114615995A (zh) PD-1、TGFβ和ATM联合抑制与放疗联合用于癌症治疗
TR201908138T4 (tr) Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
EP4422757A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
US20190358320A1 (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant